Abstract:ENPP1 expression correlates with poor prognosis in many cancers, and we previously discovered that ENPP1 is the dominant hydrolase of extracellular cGAMP: a cancer-cell-produced immunotransmitter that activates the anticancer STING pathway. However, ENPP1 has other catalytic activities and the molecular and cellular mechanisms contributing to its tumorigenic effects remain unclear. Here, using single cell RNA-seq (scRNA-seq), we show that ENPP1 overexpression drives primary breast tumor growth and metastasis by synergistically dampening extracellular cGAMP-STING mediated antitumoral immunity and activating immunosuppressive extracellular adenosine (eADO) signaling. In addition to cancer cells, stromal and immune cells in the tumor microenvironment (TME) also express ENPP1 that restrains their response to tumor-derived cGAMP. Enpp1 loss-of-function in both cancer cells and normal tissues slowed primary tumor initiation and growth and prevented metastasis in an extracellular cGAMP- and STING-dependent manner. Selectively abolishing the cGAMP hydrolysis activity of ENPP1 phenocopied total ENPP1 knockout, demonstrating that restoration of paracrine cGAMP-STING signaling is the dominant anti-cancer mechanism of ENPP1 inhibition. Strikingly, we find that breast cancer patients with low ENPP1 expression have significantly higher immune infiltration and improved response to therapeutics impacting cancer immunity upstream or downstream of the cGAMP-STING pathway, like PARP inhibitors and anti-PD1. Altogether, selective inhibition of ENPP1's cGAMP hydrolase activity alleviates an innate immune checkpoint to boost cancer immunity and is therefore a promising therapeutic approach against breast cancer that may synergize with other cancer immunotherapies.

Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint

Identification of extracellular membrane protein ENPP3 as a major cGAMP hydrolase, cementing cGAMP's role as an immunotransmitter

Identification of extracellular membrane protein ENPP3 as a major cGAMP hydrolase, cementing cGAMP’s role as an immunotransmitter

ENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway

Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer

Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone

Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP

SMPDL3A is a Cgamp-Degrading Enzyme Induced by LXR-mediated Lipid Metabolism to Restrict Cgas-Sting DNA Sensing.

Re-awakening Innate Immune Signaling in Cancer: The Development of Highly Potent ENPP1 Inhibitors

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects

Identification and Characterization of Phosphodiesterases That Specifically Degrade 3′3′-Cyclic GMP-AMP

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy

ENPP1 Immunobiology as a Therapeutic Target

Identification and characterization of phosphodiesterases that specifically degrade 3’3’-cyclic GMP-AMP (INM2P.358)

Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression

cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling.